These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Decrease of resistance to imatinib in leukaemia. Bakalova R; Zhelev Z; Ohba H Lancet; 2002 May; 359(9319):1776-7. PubMed ID: 12049890 [No Abstract] [Full Text] [Related]
13. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. Druker BJ J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403 [No Abstract] [Full Text] [Related]
14. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology? Gambacorti C Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608 [No Abstract] [Full Text] [Related]
15. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Melo JV; Chuah C Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121 [TBL] [Abstract][Full Text] [Related]
17. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia. Richardson MW; Grewal SS Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313 [No Abstract] [Full Text] [Related]
18. Imatinib and chronic-phase leukemias. Boros LG; Lee WN; Cascante M N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546 [No Abstract] [Full Text] [Related]
19. CML: imatinib mesylate (Glivec) or something else? Ghosh A Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026 [No Abstract] [Full Text] [Related]
20. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation. Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908 [No Abstract] [Full Text] [Related] [Next] [New Search]